The FDA  recalls of injectable heparin products and heparin flush solutions that may be contaminated with oversulfated chondroitin sulfate (OSCS).   Affected heparin products have been found in medical care facilities in one state since the recall announcement.  Although product recall instructions were widely distributed, they may not have been fully acted upon at all sites where heparin is used.  There have been many reports of deaths associated with allergic or hypotensive symptoms after heparin administration.  Please see FDA link at http://www.fda.gov/cder/drug/infopage/heparin/adverse_events.htm. 

The FDA asks that health professionals and facilities review and examine all drug/device storage areas, including emergency kits, dialysis units and automated drug storage cabinets to ensure that all of the recalled heparin products have been removed and are no longer available for patient use.   

Click here to view the entire press release.